콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

Z2001

Sigma-Aldrich

Zonisamide sodium salt

≥98% (HPLC), powder

동의어(들):

1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C8H7N2NaO3S
CAS Number:
68291-98-5
Molecular Weight:
234.21
MDL number:
MFCD01744844
UNSPSC 코드:
12352200
PubChem Substance ID:
24278783
NACRES:
NA.77

Quality Level

100

분석

≥98% (HPLC)

양식

powder

색상

white to beige

solubility

H2O: >5 mg/mL

주관자

Eisai

SMILES string

[Na]NS(=O)(=O)Cc1noc2ccccc12

InChI

1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1

InChI key

ZVBIRPKGWOVBLG-UHFFFAOYSA-N

유전자 정보

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

생화학적/생리학적 작용

Zonisamide sodium salt is an anti-epileptic and also scavenges nitric oxide (NO).
Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO).

특징 및 장점

This compound was developed by Eisai. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

픽토그램

Exclamation mark
GHS07

신호어

Warning

유해 및 위험 성명서

H302

예방조치 성명서

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
092M4607V
0000166037
0000166036
097K46163
097K46162

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Kouji Fukuyama et al.
Pharmaceuticals (Basel, Switzerland), 13(6) (2020-06-11)
Recent studies using the genetic partial epilepsy model have demonstrated that hyperfunction of astroglial hemichannels contributes to pathomechanism of epileptic seizure. Therefore, to explore the novel anticonvulsive mechanisms, the present study determined the effects of voltage-dependent Na+ channel (VDSC)-inhibiting anticonvulsants
S Dupont et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 29-35 (2012-11-01)
Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe
D Marazziti et al.
European review for medical and pharmacological sciences, 16(15), 2102-2107 (2013-01-03)
Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles
Kyoung Heo et al.
Seizure, 21(3), 188-193 (2012-01-10)
To evaluate the efficacy and safety of adjunctive zonisamide (ZNS) therapy in Korean adults with uncontrolled partial epilepsy. Study patients had an average of at least one seizure per 4-week (averaged over a 12-week historical baseline) despite the use of
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.